Mergers & Acquisitions
Gene therapy technology acquired by Genzyme
Published in Gene Therapy Weekly, January 19th, 2006
Under the terms of the agreement, Genzyme will acquire all of Avigen's non-pain related AAV assets. The assets include all rights to an extensive patent estate and Avigen's Parkinson's disease clinical trial program, which is in a phase I /II study currently underway at University of California, San Francisco (UCSF).
Genzyme will make an upfront cash payment of $12 million to Avigen, with additional milestone payments and royalty payments on all products developed under Avigen's comprehensive AAV intellectual property (IP) portfolio, including the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-01-19)
More Articles from Gene Therapy Weekly
- Cardiology
New technique may allow stents deliver gene therapy to patients with heart disease - DNA Research
Human RISC couples microRNA biogenesis and posttranscriptional gene silencing - Genetics & Genomics
A novel genomic DNA expression system utilizes a human artificial chromosome vector - Genetics & Genomics
Aromatase genetic variation may contribute to estrogen-dependent disease - Herpes Simplex Virus
Efficacy of oncolytic HSV-1 vectors are improved by multiple transgenes - Angiology
Beta2 -adrenergic receptor overexpression regulates angiogenesis in response to ischemia - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
